Indaptus Therapeutics is trading 10.02% up now at $1.34, with no confirmed company-specific announcement explaining the September 8 pre-market move, following a 5.17% gain to $1.22 on September 4.
- The latest filing, submitted September 4, covered a routine September 2 board-member resignation and contained no new operating catalyst.
- Broader markets are mixed to lower and do not clearly explain the isolated gain.
- The move remains unconfirmed and may reflect speculative trading or delayed attention to earlier news.